Latest News
Dapirolizumab Pegol Phase 3 Data Presented at the American College of Rheumatology Shows Significant Reduction in Systemic Lupus Erythematosus Disease Activity
GlobeNewswire - Tue Nov 19, 12:00AM CST
GlobeNewswire
Tue Nov 19, 12:00AM CST
Stocks Settle Mostly Higher on Tech Stock Strength and Lower Bond Yields
Barchart - Mon Nov 18, 3:32PM CST
Barchart
Mon Nov 18, 3:32PM CST
The S&P 500 Index ($SPX ) (SPY ) Monday closed up +0.39%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed down -0.13%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up +0.71%. Stocks on Monday settled mixed, with the Dow Jones Industrials falling to a 1-1/2...
Stocks Mostly Higher on Positive Corporate News
Barchart - Mon Nov 18, 10:15AM CST
Barchart
Mon Nov 18, 10:15AM CST
The S&P 500 Index ($SPX ) (SPY ) today is up +0.43%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -0.01%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.91%. Stocks today are mostly higher on some positive corporate news. Tesla is up more...
Market News & Analysis: November 15th, 2024
Stock Target Advisor - Fri Nov 15, 2:40PM CST
Stock Target Advisor
Fri Nov 15, 2:40PM CST
Global Markets Canadian Markets The Toronto Stock Exchange (TSX), dropped significantly as both oil and gold prices declined. The slide in commodities was largely driven by concerns over waning demand from China, the worldโs largest consumer of commodities, and a market shift due to expectations that U.S. interest rate cuts...
Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimerโs Disease
GlobeNewswire - Thu Nov 14, 10:23AM CST
GlobeNewswire
Thu Nov 14, 10:23AM CST
Eisai Presents Data on Benefits of Long-Term Administration of Dual-Acting Lecanemab at the 17th Clinical Trials for Alzheimerโs Disease (CTAD) Conference
GlobeNewswire - Wed Oct 30, 6:30PM CDT
GlobeNewswire
Wed Oct 30, 6:30PM CDT
Biogen (BIIB) Q3 2024 Earnings Call Transcript
Motley Fool - Wed Oct 30, 12:45PM CDT
Motley Fool
Wed Oct 30, 12:45PM CDT
BIIB earnings call for the period ending September 30, 2024.
Biogen and Neomorph Announce Multi-Target Research Collaborationย to Discover and Develop Molecular Glue Degraders for Alzheimerโs, Rare, and Immunological Diseases
GlobeNewswire - Tue Oct 29, 5:00PM CDT
GlobeNewswire
Tue Oct 29, 5:00PM CDT
Biogen Appoints Daniel Quirk, MD, as Chief Medical Officer
GlobeNewswire - Tue Oct 29, 7:00AM CDT
GlobeNewswire
Tue Oct 29, 7:00AM CDT
Michael McDonnell, Executive Vice President and Chief Financial Officer to Retire in February 2025
GlobeNewswire - Mon Oct 28, 7:30AM CDT
GlobeNewswire
Mon Oct 28, 7:30AM CDT
Biogen Presents Positive Results from Phase 2 IGNAZ Study of Felzartamab in IgA Nephropathy at American Society of Nephrology (ASN) Kidney Week 2024
GlobeNewswire - Sat Oct 26, 7:15PM CDT
GlobeNewswire
Sat Oct 26, 7:15PM CDT
Biogen to Present New Data at the Clinical Trials on Alzheimer's Disease (CTAD) 2024 Annual Conference
GlobeNewswire - Thu Oct 24, 6:30AM CDT
GlobeNewswire
Thu Oct 24, 6:30AM CDT
This Setback for Johnson & Johnson Is 1 More Green Light for Eli Lilly's Stock
Motley Fool - Wed Oct 23, 3:30AM CDT
Motley Fool
Wed Oct 23, 3:30AM CDT
Fewer contenders means fewer constraints on expanding market share.
Biogen Announces Late Breaker and New Data Presentations at American Society of Nephrology (ASN) Kidney Week 2024
GlobeNewswire - Tue Oct 22, 6:30AM CDT
GlobeNewswire
Tue Oct 22, 6:30AM CDT
These 3 Stocks Are Screaming Oversold: Seize the Opportunity
MarketBeat - Thu Oct 10, 8:45AM CDT
MarketBeat
Thu Oct 10, 8:45AM CDT
Micron, Biogen, and Regeneron are three stocks that appear oversold and could present substantial buying opportunities for investors seeking recovery plays.
Biogen Receives U.S. FDA Breakthrough Therapy Designation for Felzartamab for the Treatment of Antibody-Mediated Rejection in Kidney Transplant Recipients
GlobeNewswire - Wed Oct 9, 6:30AM CDT
GlobeNewswire
Wed Oct 9, 6:30AM CDT
New Higher Dose Nusinersen Efficacy and Safety Data Presented at World Muscle Society Congress, Highlight Potential to Maximize Benefit of Nusinersen in SMA
GlobeNewswire - Tue Oct 8, 6:30AM CDT
GlobeNewswire
Tue Oct 8, 6:30AM CDT
1 Unstoppable Growth Stock Heading to $2 Trillion by 2030
Motley Fool - Sat Sep 28, 4:45AM CDT
Motley Fool
Sat Sep 28, 4:45AM CDT
It's hard to bet against this company right now.
UCB and Biogen Announce Positive Topline Results From Phase 3 Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus and are Initiating Second Phase 3 Study in 2024
GlobeNewswire - Tue Sep 24, 12:00AM CDT
GlobeNewswire
Tue Sep 24, 12:00AM CDT
Biogen Board Appoints Two New Independent Directors
GlobeNewswire - Thu Sep 12, 6:30AM CDT
GlobeNewswire
Thu Sep 12, 6:30AM CDT
Biogen Announces Positive Topline Results from Study of Higher Dose Regimen of Nusinersen, Showing Significant Benefit in Treatment of SMA
GlobeNewswire - Wed Sep 4, 6:30AM CDT
GlobeNewswire
Wed Sep 4, 6:30AM CDT
These 3 Factors Could Make Eli Lilly Stock a Better Buy Than Novo Nordisk Right Now
Motley Fool - Sat Aug 31, 6:10AM CDT
Motley Fool
Sat Aug 31, 6:10AM CDT
This competitive showdown just saw one of the players hit a couple of bumps.
Prediction: The Next Big Biotech Stock Boom Will Be in Longevity Drugs
Motley Fool - Tue Aug 13, 12:14PM CDT
Motley Fool
Tue Aug 13, 12:14PM CDT
Investing based on the segment's long-term prospects is likely to be very lucrative.
New Study Reveals How Classical Music Could Revolutionize Depression Care
PressReach - Mon Aug 12, 9:15AM CDT
PressReach
Mon Aug 12, 9:15AM CDT
In a groundbreaking study, Chinese scientists have revealed that classical music could be a powerful tool in the fight against treatment-resistant depression, a condition that affects nearly 50% of patients with major depressive disorder (MDD)....
A Blood Test Could Detect Early Alzheimer's. That Could Make These 2 Stocks Red-Hot Buys.
Motley Fool - Sun Aug 11, 8:05AM CDT
Motley Fool
Sun Aug 11, 8:05AM CDT
These companies have approved Alzheimer's treatments that could generate billions in revenue for their respective businesses.